Diabetic Neuropathies Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
The study consists of two periods, the Screening Period (~3 weeks) and Treatment Period (12
weeks).
Eligibility for the study will be determined by Screening tests, physical
examination/medical history, and fulfilment of eligibility criteria including assessment of
pain completed during the Screening Period. Potential participants will be required to
provide written informed consent prior to any study-specific Screening procedures being
performed.
Following Screening assessments, patients will be randomized to receive either EMA401 300 mg
BID or placebo.
Patient study visits during the Treatment Period are at the end of baseline/randomization
visit, and end of Weeks 3, 6, 9, and 12, for assessments.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with Type I or Type II diabetes mellitus with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least six months duration. - Be assessed as suffering from moderate to severe pain across the Screening Period. The assessment of moderate and severe pain will be made using an algorithm proprietary to Spinifex. The investigator/site staff will be informed immediately as to whether the patient is eligible or ineligible on the ePRO website based on the patient entering all relevant pain scores in the eDiary device. - Women of child bearing potential (WOCBP), must have a negative urine pregnancy test at the Screening visit (Visit 1) and within 72 hours prior to administration of IP. Exclusion Criteria: - Patients taking any topical treatment for their PDN at the time of Screening Visit 2 will be excluded, including lidocaine plaster, capsaicin patch, and any other topical preparations of these or any other topical medications (e.g., aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for their PDN. - Have a blood pressure reading, after resting for at least five minutes, outside a systolic blood pressure range of 84 - 151 mmHg or a diastolic blood pressure > 95 mmHg. If the blood pressure is outside of the range, a repeat measurement can be taken after the patient has rested. The repeat measurement should be used as the screening value. - Have serum aspartate transaminase (AST), or alanine transaminase (ALT) levels > 1.5 x the upper limit of normal or have total bilirubin concentrations > 1.5 x the upper limit of normal at Screening (Visit 1). - Have hemoglobin A1c > 11 %. - Known history of, or positive laboratory results for hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection as defined by being seropositive for hepatitis B surface antigen (HBsAg), HCV antibodies or HIV antibodies respectively. - Have undergone neurolytic or neurosurgical therapy or use a neurostimulating device for PDN. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Spinifex Pharmaceuticals Pty Ltd | INC Research |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS). | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo on the BPI-SF interference total score. | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo on the weekly mean of the 24 hour worst NRS pain score. | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo, on the Patient Global Impression of Change (PGIC). | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo on the Brief Pain Inventory-Short Form (BPI-SF) average pain score. | Change from Baseline to Week 12 | No | |
Secondary | The proportion of EMA401 patients achieving a = 30% and a = 50% reduction in weekly mean 24 hour average pain score compared to placebo (i.e., responder rates). | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo on the Neuropathic Pain Symptom Inventory (NPSI). | Change from Baseline to Week 12 | No | |
Secondary | The effect of EMA401 compared to placebo on the Insomnia Severity Index (ISI). | Change from Baseline to Week 12 | No | |
Secondary | The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events. | Change from Baseline to Week 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05683106 -
Effects of Customized Silicone Digital Orthoses in People With Diabetic Neuropathy
|
N/A | |
Withdrawn |
NCT04106050 -
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
|
Phase 1 | |
Completed |
NCT04088929 -
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT01939366 -
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
|
Phase 2 | |
Withdrawn |
NCT00815932 -
The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy
|
N/A | |
Completed |
NCT01926522 -
Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients
|
N/A | |
Not yet recruiting |
NCT01180608 -
Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain
|
N/A | |
Completed |
NCT00380913 -
Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
|
Phase 4 | |
Completed |
NCT00760955 -
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Terminated |
NCT00756041 -
Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT05255497 -
The Effect of Sensorial Biodex Balance Balance System Exercises in Diabetic Neuropathy
|
N/A | |
Completed |
NCT06061237 -
Effects of Aerobic Thai Dance in Patient With Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT02915263 -
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
|
Phase 2 | |
Enrolling by invitation |
NCT05043636 -
Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
|
||
Completed |
NCT06373809 -
Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy
|
Early Phase 1 | |
Completed |
NCT05968131 -
Comparative Effects of Proprioceptive Training and Routine Physical Therapy on Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00282685 -
Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy
|
Phase 1 | |
Completed |
NCT00135109 -
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT06292962 -
Evaluating the Impact of Vagus Nerve Stimulation on Diabetic Peripheral Neuropathic Pain
|
N/A | |
Completed |
NCT05058807 -
Effects of Whole Body Vibration in Diabetic Peripheral Neuropathy .
|
N/A |